Current Cancer Therapy Reviews
Title:Editorial (Thematic Issue: Current Treatments for Skin Cancer Part 2)
Volume: 12 Issue: 3
Author(s): Edward Yu, Kurian Joseph and Patricia Tai
Affiliation:
Export Options
About this article
Cite this article as:
Yu Edward, Joseph Kurian and Tai Patricia, Editorial (Thematic Issue: Current Treatments for Skin Cancer Part 2), Current Cancer Therapy Reviews 2016; 12 (3) . https://dx.doi.org/10.2174/157339471203170208201336
DOI https://dx.doi.org/10.2174/157339471203170208201336 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic:New Research Tolls for Antique Pediatric Tumors:The Dilemma of Transposing Drug-Resistance (Guest Editor: E.T. Valera)]
Current Pharmaceutical Biotechnology The Interest of Folic Acid in Targeted Photodynamic Therapy
Current Medicinal Chemistry Synthesis and characterization of a new retinoic acid ECPIRM as potential chemotherapeutic agent for human cutaneous squamous carcinoma
Anti-Cancer Agents in Medicinal Chemistry Repair and Translesion DNA Polymerases as Anticancer Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Advances and Perspectives in Cell-Specific Aptamers
Current Pharmaceutical Design SNAP-Tag Technology: A Powerful Tool for Site Specific Conjugation of Therapeutic and Imaging Agents
Current Pharmaceutical Design NCRNA Combined Therapy as Future Treatment Option for Cancer
Current Pharmaceutical Design Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Current Drug Targets Oncogenomics
Current Drug Metabolism Subject Index to Volume 3
Current Drug Targets - Infectious Disorders Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs
Current Medicinal Chemistry Therapeutic Targeting of Apoptotic Pathways in Cancer
Current Drug Targets Opioid Growth Factor and its Derivatives as Potential Non-toxic Multifunctional Anticancer and Analgesic Compounds
Current Medicinal Chemistry Lymphatic Delivery of Anti-HIV Drug Nanoparticles
Recent Patents on Nanotechnology Meet Our Editorial Board Member:
Reviews on Recent Clinical Trials Physiological Proteins in Therapeutics: A Current Review on Interferons
Mini-Reviews in Medicinal Chemistry In-Vitro Antiproliferative Activity of New Tetrahydroisoquinolines (THIQs) on Ishikawa Cells and their 3D Pharmacophore Models
Letters in Drug Design & Discovery Editorial [Hot topic: Newly Recognized Actions of Vitamin D3 (Guest Editor: Ilka Nemere)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases
Current Drug Targets Biosynthetic and Metabolic Alterations in Cancer Growth
Current Angiogenesis (Discontinued)